NLRP3 and Hepatic fibrosis: Similarly, in a study of a mouse model of liver fibrosis, LPS/ATP treatment increases the contents of cathepsin B and ROS and activates NLRP3 inflammasome, while LPS/ATP and cathepsin B inhibitors fails to increase levels of NLRP3 and IL-1β [52].